Home›Stock Screener›Beta Drugs

Beta Drugs Share Price Today | Stock Price & Beta Drugs Share Screener

BETA Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1802.30
▲ 9.80 (0.55%)
2026-11-18 00:00:00

As of November 18, 2026, the live Beta Drugs share price (NSE: BETA) is ₹1,802.30, up 0.55% from the previous close, with shares trading between ₹1,765.80 and ₹1,841.50 in today's trading session, and a 52-week range of ₹1,030.30–₹2,668.30. Track BETA market capitalization to gauge the company's total market size. Use the Beta Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Beta Drugs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹97 and net income of ₹9, with EBITDA of ₹21, an operating margin of 19.0% and a profit margin of 9.3%.

Beta Drugs Market Cap ₹2,004.38 Cr.
BETA P/E Ratio (TTM) 37.40
Beta Drugs P/B Ratio 4.55
EPS (TTM) ₹40.92
Dividend Yield -
Debt to Equity 0.65
BETA 52 Week High ₹2668.30
Beta Drugs 52 Week Low ₹1030.30
Operating Margin 19.00%
Profit Margin 9.28%
BETA Revenue (TTM) ₹97.00
EBITDA ₹21.00
Net Income ₹9.00
Total Assets ₹496.00
Total Equity ₹245.00

Beta Drugs Share Price Chart

Track the current stock price of Beta Drugs with an interactive chart. Analyse BETA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Beta Drugs stock quote in one place.

The quote of ₹1,802.30 sits between the 52-week low of ₹1,030.30 and the 52-week high of ₹2,668.30, and the latest session moved 0.55% from the previous close.

Beta Drugs Company Profile - Fundamental Screener

Screen Beta Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BETA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE351Y01019.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE351Y01019

Beta Drugs Balance Sheet Screener

Screen BETA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹496, up from ₹436 in 2025.

Latest statistics put total assets at ₹496 and shareholder funds at ₹245, with a leverage ratio of 0.65.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018

Assets

Total Assets 496 436 254 198 158 118 107 83 50
Current Assets 0 0 0 0 0 0 0 0 0
Fixed Assets 125 89 65 63 55 40 44 18 13

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0
Current Liabilities 143 136 12 13 17 16 13 9 3
Non-Current Liabilities 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 245 197 157 123 92 69 57 41 33
Share Capital 10 10 10 10 10 10 10 9 9
Reserves & Surplus 235 187 148 113 83 59 48 32 24

Beta Drugs Income Statement Screener - Profit & Revenue Analysis

Screen Beta Drugs income statement and profit fundamentals. Analyze BETA quarterly results. Beta Drugs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹97 and net profit was ₹9, equal to earnings per unit of ₹8.93, at an operating margin of 19%.

In that period expenses were ₹76, interest cost ₹4 and tax ₹3. The next period listed, 2026-Jun, shows revenue of ₹127 and net profit of ₹17.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Dec

Revenue and Expenses

Revenue 97 127 139 98 103 106 90 89
Expenses 76 98 107 79 81 82 70 72

Operating Costs and Margins

EBITDA 21 29 32 19 23 24 19 17
Operating Profit % 19.00% 22.00% 22.00% 16.00% 20.00% 21.00% 19.00% 18.00%
Depreciation 5 4 5 4 4 4 4 3
Interest 4 3 2 3 3 4 4 2

Profit and Earnings

Profit Before Tax 12 22 26 12 16 16 11 12
Tax 3 6 7 3 4 4 2 3
Net Profit 9 17 19 9 12 12 9 9
EPS 8.93 14.78 16.59 9.40 11.59 12.10 8.40 9.31

Beta Drugs Cash Flow Screener - Liquidity Fundamentals

Screen BETA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹36, and net cash flow was an inflow of ₹118.

Over the same period, investing activities used ₹36 and financing activities provided ₹118.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Cash from Operations and Investing

Operating Activities 36 31 23 30 19 8 0 17
Investing Activities -36 -14 -19 -22 -6 -15 -21 -11

Financing and Net Cash

Financing Activities 118 -8 -3 -1 -8 9 12 5
Net Cash Flow 118 10 2 7 5 2 -9 12

Beta Drugs Shareholding Pattern Screener

See Beta Drugs shareholding pattern with promoter, FII, and DII holdings. Check Beta Drugs promoter holding and ownership changes for BETA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 66.73%, foreign institutions 0.90%, domestic institutions 0.29% and the public 21.81%, spread across 3,184 shareholders.

The shareholder count was 3,184 in 2026-Mar, compared with 5,027 in 2026-May.

Item 2026-Mar 2026-May 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Nov

Promoter Holding

Promoter Holding 66.73% 59.10% 59.10% 58.91% 66.73% 66.73% 66.73% 66.73%

Institutional Investors

FII Holding 0.90% 2.95% 1.02% 1.37% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.29% 6.01% 6.23% 6.45% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 21.81% 22.72% 24.30% 22.00% 21.81% 21.75% 21.81% 21.78%
Other Holding 10.26% 9.22% 9.35% 11.27% 11.45% 11.51% 11.45% 11.49%
Shareholder Count 3,184 5,027 7,359 10,145 3,045 3,139 3,184 3,003

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Beta Drugs. Beta Drugs dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Beta Drugs.

Beta Drugs Stock Index Membership - Nifty & Sensex

See which indices include Beta Drugs stock. Check BETA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Beta Drugs is not part of any tracked indices.
Only major market indices are tracked in our system.

Beta Drugs Market Events Screener - Corporate Actions

Get Beta Drugs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Beta Drugs stock events that may affect BETA share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 22, 2026, with a record date of October 22, 2026.

It is followed by Quarterly Result Announcement dated July 20, 2026 and Quarterly Result Announcement dated May 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-22 2026-10-22 Quarterly Result Announcement NA -2.05%
2026-07-20 2026-07-20 Quarterly Result Announcement NA -3.51%
2026-05-14 2026-05-14 Quarterly Result Announcement NA 7.15%
2026-02-14 2026-02-14 Quarterly Result Announcement NA -2.75%
2026-02-04 2026-02-04 Extraordinary General Meeting NA -9.19%
2025-11-06 2025-11-06 Quarterly Result Announcement NA -6.03%
2025-05-15 2025-05-15 Quarterly Result Announcement NA 5.92%
2025-03-26 2025-03-26 Bonus 1:20 4.59%
2024-12-21 2024-12-21 Extraordinary General Meeting NA -6.02%
2024-11-12 2024-11-12 Extraordinary General Meeting NA 15.13%
2024-11-06 2024-11-06 Quarterly Result Announcement NA -1.38%
2024-09-30 2024-09-30 Annual General Meeting NA -1.01%

Beta Drugs Competitors Screener - Peer Stocks Comparison

Screen BETA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 449,036 40.80 61,674 12.69% 11,565 60.77
Divis Laboratories 293,316 87.70 11,067 13.95% 2,568 65.94
Torrent Pharmaceuticals 175,376 84.70 13,886 20.34% 2,138 42.26
Laurus Labs 125,488 94.90 6,868 22.01% 890 55.82
Zydus Life Science 119,900 27.90 27,658 17.64% 5,026 55.22
Dr Reddys Laboratories 116,705 42.00 35,059 3.90% 4,158 73.09
Cipla 114,474 39.20 29,045 2.24% 3,870 62.07
Mankind Pharma 108,424 47.50 14,636 14.85% 1,938 62.66
Aurobindo Pharma 103,355 25.90 34,145 5.56% 3,503 60.69
Lupin 90,173 17.10 29,039 26.75% 5,356 44.73

Beta Drugs Company Announcements - News & Reports Screener

Screen BETA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 13, 2026 and November 13, 2026.

Date Update Actions
2026-11-17 Trading Window -
2026-11-13 Monitoring Agency Report -
2026-11-13 Monitoring Agency Report -
2026-11-02 Updates -
2026-10-28 Analysts/Institutional Investor Meet/Con. Call Updates -
2026-10-23 Copy of Newspaper Publication -
2026-10-22 Statement of deviation(s) or variation(s) under Reg. 32 -
2026-10-22 Analysts/Institutional Investor Meet/Con. Call Updates -
2026-10-22 Analysts/Institutional Investor Meet/Con. Call Updates -
2026-10-22 Outcome of Board Meeting -
2026-10-16 Analysts/Institutional Investor Meet/Con. Call Updates -
2026-10-16 Analysts/Institutional Investor Meet/Con. Call Updates -
2026-10-06 Certificate under SEBI (Depositories and Participants) Regulations, 2018 -
2026-10-01 Shareholders meeting -
2026-09-30 Shareholders meeting -
2026-09-30 Trading Window -
2026-09-22 General Updates -
2026-09-10 Analysts/Institutional Investor Meet/Con. Call Updates -
2026-09-07 Copy of Newspaper Publication -
2026-09-05 Shareholders meeting -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,802.30, within a 52-week range of ₹1,030.30 to ₹2,668.30. The P/E ratio is 37.40 and the P/B ratio is 4.55, with earnings per unit of ₹40.92. Market capitalisation stands at ₹2,004.38 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE. Key statistics were last updated on November 19, 2026. This page covers 9 balance sheet periods, 8 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.